AI Summary

A recent trial involving CAR-T therapy has yielded promising results for high-risk patients with smoldering multiple myeloma. The trial, which involved the use of CAR-T cell therapy Carvykti, demonstrated potential in preventing the progression of smoldering multiple myeloma to the more severe form of the disease. The implications of this development are still being assessed, but the results suggest that CAR-T therapy may offer a new avenue for treatment in high-risk patients.

AI summaries can be wrong sometimes—always verify important details using the source article.